ADC Therapeutics (ADCT) Profit After Tax (2020 - 2026)

ADC Therapeutics has disclosed Profit After Tax across 5 years of filings, most recently posting -$33.0 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$33.0 million, up 14.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$137.0 million (up 8.99% YoY), and the FY2025 annual result was -$142.6 million, up 9.64% from the prior year.
• Profit After Tax came in at -$33.0 million for Q1 2026 at ADC Therapeutics, down from -$6.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$6.4 million in Q4 2025 to a low of -$85.0 million in Q4 2023.
• The 4-year median for Profit After Tax is -$43.7 million (2024), against an average of -$44.0 million.
• Peak annual rise in Profit After Tax reached 80.14% in 2025, while the deepest fall reached 57.58% in 2025.
• ADC Therapeutics' Profit After Tax stood at -$85.0 million in 2023, then jumped by 62.05% to -$32.3 million in 2024, then surged by 80.14% to -$6.4 million in 2025, then plunged by 414.4% to -$33.0 million in 2026.
• The last three Profit After Tax figures came in at -$33.0 million (Q1 2026), -$6.4 million (Q4 2025), and -$41.0 million (Q3 2025), per Business Quant data.